Investment Rating - The report maintains a "Buy" rating for the company [7][5]. Core Views - The report highlights that Kangyuan Pharmaceutical, as a leader in innovative traditional Chinese medicine, is expected to stabilize its revenue in Q2 2025 due to the easing of compliance impacts and a return to normalcy in seasonal flu incidence [1][4]. - The acquisition of 100% of Zhongxin Pharmaceutical is anticipated to enhance the company's value through the development of innovative biopharmaceuticals, with significant data readouts expected from ongoing projects in 2025 and 2026 [1][3]. Summary by Sections Company Overview - Kangyuan Pharmaceutical acquired Zhongxin Pharmaceutical for 270 million RMB, with Zhongxin currently not profitable and having a net asset of -423 million RMB as of 9M24 [2]. - Zhongxin's clinical pipeline includes four core products, with an estimated funding requirement of 400 million RMB for clinical trials [2]. Financial Performance - The company's revenue is projected to recover in 2025, with expected revenue growth of 8.4% in 2025 and 10.48% in 2026 [11]. - The net profit attributable to the parent company is forecasted to be 4.4 billion RMB in 2025, 5.1 billion RMB in 2026, and 5.8 billion RMB in 2027, reflecting a growth rate of 12.26% and 15.43% respectively [11][5]. Valuation - The target price for the company is set at 17.09 RMB, based on a 22x PE ratio for 2025, which reflects a premium over the average PE of comparable companies at 15x [5][12]. - The report anticipates that the company's innovative pipeline and product portfolio will drive high growth potential post-compliance challenges [5][3].